Subtype
Urinary System Carcinoma
CI-CAN-00004182Explore in graph →
672 active trials25 approved drugs88 evidence items
- NCIt
- C181197
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004182Explore in graph →
Clinical trials
2,398 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (392)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06656039 | A Multimodal Predictive Recurrence Score for Patients With Clear Cell Renal Cell Carcinoma | completed | — | 1,200 | RenJi HospitalOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT04883827 | Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer | completed | — | 180 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT04005183 | Renal Cell Carcinoma Microenvironment Discovery Project(REMEDY) | completed | — | 146 | University Health Network, TorontoOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT03109015 | Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing(ASSET) | completed | Phase 2 | 7 | Duke UniversityOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06607809 | Inflammatory Markers (ICC, MCVL) and Nivolumab Response: Predicting Immunotherapy Success in Metastatic RCC(IMNR) | completed | — | 99 | Dr. Lutfi Kirdar Kartal Training and Research HospitalOTHER_GOV | 1 | Oct 8, 2024 | clinicaltrials |
| NCT02667886 | Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 74 | X4 PharmaceuticalsINDUSTRY | 2 | Oct 3, 2024 | clinicaltrials |
| NCT05363072 | A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland. | completed | — | 1,112 | PfizerINDUSTRY | 1 | Oct 1, 2024 | clinicaltrials |
| NCT01210482 | Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) | completed | — | 1,050 | PfizerINDUSTRY | 1 | Sep 25, 2024 | clinicaltrials |
| NCT03108066 | MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003) | completed | Phase 2 | 4 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Sep 24, 2024 | clinicaltrials |
| NCT04375150 | Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC | completed | — | 355 | PfizerINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05136898 | Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) | completed | Phase 3 | 8 | UroGen Pharma Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05485896 | Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC | completed | Phase 2 | 23 | Tianjin Medical University Second HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05399004 | Evaluating Sexual Function in Women Undergoing a Radical Cystectomy for Bladder Cancer | completed | — | 34 | Mayo ClinicOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT03334344 | Using Virtual Reality (VR) Models for Preoperative Planning | completed | N/A | 92 | Ceevra, Inc.INDUSTRY | 1 | Aug 29, 2024 | clinicaltrials |
| NCT00554515 | The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma(SELECT) | completed | Phase 2 | 123 | Beth Israel Deaconess Medical CenterOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT00655655 | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 96 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT05112627 | Immunophenotyping in Metastatic Kidney Cancer Patients Receiving Ablative Therapy | completed | — | 15 | Mayo ClinicOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT02773849 | ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) | completed | Phase 3 | 157 | Ferring PharmaceuticalsINDUSTRY | 1 | Jul 29, 2024 | clinicaltrials |
| NCT03513952 | Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Jul 26, 2024 | clinicaltrials |
| NCT03752398 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)(DUET-3) | completed | Phase 1 | 198 | Xencor, Inc.INDUSTRY | 1 | Jul 5, 2024 | clinicaltrials |
| NCT03200587 | Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC) | completed | Phase 1 | 12 | University of UtahOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT03502330 | APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma | completed | Phase 1 | 42 | Yale UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT03557918 | Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer | completed | Phase 2 | 26 | Matthew GalskyOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT03829111 | CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer | completed | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT00026663 | Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance | completed | — | 86 | National Cancer Institute (NCI)NIH | 1 | Jul 1, 2024 | clinicaltrials |
| NCT02408406 | PatientCareAnywhere Internet-Based Software in Improving Communication and Education in Patients With Cancer and Their Healthcare Providers | completed | N/A | 140 | City of Hope Medical CenterOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT02808143 | Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer | completed | Phase 1 | 9 | Northwestern UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT01002937 | Novel Prognostic Markers in Renal Cancer | completed | — | 182 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 18, 2024 | clinicaltrials |
| NCT04518046 | Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies | completed | Phase 1 | 22 | Mirati Therapeutics Inc.INDUSTRY | 1 | Jun 5, 2024 | clinicaltrials |
| NCT03776123 | Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients | completed | — | 347 | IpsenINDUSTRY | 1 | May 29, 2024 | clinicaltrials |
| NCT03629756 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | completed | Phase 1 | 48 | Arcus Biosciences, Inc.INDUSTRY | 2 | May 24, 2024 | clinicaltrials |
| NCT04752267 | 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases | completed | Early Phase 1 | 10 | University of Southern CaliforniaOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT03849118 | 89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study(89ZR-TLX250) | completed | Phase 3 | 300 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 8 | May 17, 2024 | clinicaltrials |
| NCT00831857 | VEGF Imaging in Renal Cell Carcinoma(Renimage) | completed | — | 26 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT00970970 | Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease(VHLimage) | completed | — | 22 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT01028638 | Vascular Endothelial Growth Factor (VEGF) Imaging Before and During Everolimus Treatment for Renal Cell Carcinoma(Everolimage) | completed | — | 13 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT01398306 | Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.(BANN) | completed | — | 40 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT03097328 | Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma | completed | Phase 2 | 39 | Bradley A. McGregor, MDOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT06380062 | Choline Metabolites in People With Prostate Cancer and Those With Benign Hyperplasia | completed | — | 350 | Universität des SaarlandesOTHER | 1 | Apr 25, 2024 | clinicaltrials |
| NCT05046665 | Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer Patients(ZiPUP) | completed | Phase 1 | 11 | South Metropolitan Health ServiceOTHER_GOV | 1 | Apr 22, 2024 | clinicaltrials |
| NCT03329950 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | completed | Phase 1 | 132 | Celldex TherapeuticsINDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT05375136 | A Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients | completed | — | 135 | Eisai Korea Inc.INDUSTRY | 1 | Mar 25, 2024 | clinicaltrials |
| NCT03590054 | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | completed | Phase 1 | 35 | Rahul AggarwalOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT06317207 | Evaluation of the Safety of Reoperation for Ipsilateral Recurrent Tumors After Nephron-sparing Partial Nephrectomy(LiangAH) | completed | — | 15 | The First Affiliated Hospital of Anhui Medical UniversityOTHER | 0 | Mar 19, 2024 | clinicaltrials |
| NCT02762006 | Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma | completed | Phase 1 | 29 | Moshe OrnsteinOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT03126331 | Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab | completed | Phase 2 | 26 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT03339843 | Multiorgan Metabolic Imaging Response Assessment of Abemaciclib(MiMe-A) | completed | Phase 2 | 85 | Jules Bordet InstituteOTHER | 2 | Mar 15, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Oct 24, 2024source: clinicaltrials